Janux Therapeutics (JANX) CMO William Go files Form 3 showing no share ownership

Rhea-AI Filing Summary

Janux Therapeutics, Inc. Chief Medical Officer William Go filed an initial ownership report on Form 3. The filing states that no Janux common stock or derivative securities are beneficially owned. This establishes his baseline insider ownership position as zero under SEC reporting rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 02/04/2026 - 08:00 PM Learn about SEC filing dates

FAQ

What does the JANX Form 3 filing by William Go disclose?

The Form 3 filing shows that Chief Medical Officer William Go currently reports no beneficial ownership of Janux Therapeutics securities. This initial statement sets his baseline insider position for future SEC ownership reporting requirements.

Does Janux Therapeutics (JANX) report any shares owned by William Go?

No. The Form 3 for Janux Therapeutics (JANX) states that no securities are beneficially owned by Chief Medical Officer William Go. Both the non-derivative and derivative security tables report zero beneficial ownership at the time of the filing.

What is William Go’s role at Janux Therapeutics (JANX) in this Form 3?

In this Form 3, William Go is identified as an officer of Janux Therapeutics, serving as Chief Medical Officer. The filing confirms his role but reports no current beneficial ownership of Janux securities.

Are there any transactions reported in the JANX Form 3 for William Go?

No transactions are reported. The Form 3 for Janux Therapeutics (JANX) only provides an initial ownership statement for William Go and specifies that no securities are beneficially owned, with no purchases, sales, or grants listed.

Why is Janux Therapeutics (JANX) filing a Form 3 for its Chief Medical Officer?

Form 3 is required when someone becomes an SEC-reportable insider, such as a key officer. Janux Therapeutics (JANX) filed this for Chief Medical Officer William Go to establish his initial ownership status, which is reported as zero beneficially owned securities.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Go William

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/26/2026

3. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ James Pennington, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.